Global drug firms may cut their South African investments as part of a campaign against Pretoria's plans to overhaul its intellectual property laws to favour generic production, media documents show.
South Africa is in the final stages of implementing a new law that would allow generic drug makers t
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
BusinessDay
Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more
